GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy
- PMID: 34335968
- PMCID: PMC8315064
- DOI: 10.7150/thno.58655
GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy
Abstract
Radiotherapy is one of the curative treatment options for localized prostate cancer (PCa). The curative potential of radiotherapy is mediated by irradiation-induced oxidative stress and DNA damage in tumor cells. However, PCa radiocurability can be impeded by tumor resistance mechanisms and normal tissue toxicity. Metabolic reprogramming is one of the major hallmarks of tumor progression and therapy resistance. Specific metabolic features of PCa might serve as therapeutic targets for tumor radiosensitization and as biomarkers for identifying the patients most likely to respond to radiotherapy. The study aimed to characterize a potential role of glutaminase (GLS)-driven glutamine catabolism as a prognostic biomarker and a therapeutic target for PCa radiosensitization. Methods: We analyzed primary cell cultures and radioresistant (RR) derivatives of the conventional PCa cell lines by gene expression and metabolic assays to identify the molecular traits associated with radiation resistance. Relative radiosensitivity of the cell lines and primary cell cultures were analyzed by 2-D and 3-D clonogenic analyses. Targeting of glutamine (Gln) metabolism was achieved by Gln starvation, gene knockdown, and chemical inhibition. Activation of the DNA damage response (DDR) and autophagy was assessed by gene expression, western blotting, and fluorescence microscopy. Reactive oxygen species (ROS) and the ratio of reduced glutathione (GSH) to oxidized glutathione (GSSG) were analyzed by fluorescence and luminescence probes, respectively. Cancer stem cell (CSC) properties were investigated by sphere-forming assay, CSC marker analysis, and in vivo limiting dilution assays. Single circulating tumor cells (CTCs) isolated from the blood of PCa patients were analyzed by array comparative genome hybridization. Expression levels of the GLS1 and MYC gene in tumor tissues and amino acid concentrations in blood plasma were correlated to a progression-free survival in PCa patients. Results: Here, we found that radioresistant PCa cells and prostate CSCs have a high glutamine demand. GLS-driven catabolism of glutamine serves not only for energy production but also for the maintenance of the redox state. Consequently, glutamine depletion or inhibition of critical regulators of glutamine utilization, such as GLS and the transcription factor MYC results in PCa radiosensitization. On the contrary, we found that a combination of glutamine metabolism inhibitors with irradiation does not cause toxic effects on nonmalignant prostate cells. Glutamine catabolism contributes to the maintenance of CSCs through regulation of the alpha-ketoglutarate (α-KG)-dependent chromatin-modifying dioxygenase. The lack of glutamine results in the inhibition of CSCs with a high aldehyde dehydrogenase (ALDH) activity, decreases the frequency of the CSC populations in vivo and reduces tumor formation in xenograft mouse models. Moreover, this study shows that activation of the ATG5-mediated autophagy in response to a lack of glutamine is a tumor survival strategy to withstand radiation-mediated cell damage. In combination with autophagy inhibition, the blockade of glutamine metabolism might be a promising strategy for PCa radiosensitization. High blood levels of glutamine in PCa patients significantly correlate with a shorter prostate-specific antigen (PSA) doubling time. Furthermore, high expression of critical regulators of glutamine metabolism, GLS1 and MYC, is significantly associated with a decreased progression-free survival in PCa patients treated with radiotherapy. Conclusions: Our findings demonstrate that GLS-driven glutaminolysis is a prognostic biomarker and therapeutic target for PCa radiosensitization.
Keywords: Autophagy; Cancer stem cells; GLS1; Prostate cancer; Radioresistance.
© The author(s).
Conflict of interest statement
Competing Interests: In the past 5 years, Dr. Mechthild Krause received funding for her research projects by IBA (2016), Merck KGaA (2014-2018 for preclinical study; 2018-2020 for clinical study), Medipan GmbH (2014-2018). In the past 5 years, Dr. Krause, Dr. Linge and Dr. Löck have been involved in an ongoing publicly funded (German Federal Ministry of Education and Research) project with the companies Medipan, Attomol GmbH, GA Generic Assays GmbH, Gesellschaft für medizinische und wissenschaftliche genetische Analysen, Lipotype GmbH and PolyAn GmbH (2019-2021). For the present manuscript, none of the above mentioned funding sources were involved. In the past 5 years, Dr. Michael Baumann received funding for his research projects and for educational grants to the University of Dresden by Bayer AG (2016-2018), Merck KGaA (2014-open) and Medipan GmbH (2014-2018). He is on the supervisory board of HI-STEM gGmbH (Heidelberg) for the German Cancer Research Center (DKFZ, Heidelberg) and also member of the supervisory body of the Charité University Hospital, Berlin. As former chair of OncoRay (Dresden) and present CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg), he has been or is responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he has discussed potential projects and signed contracts for research funding and/or collaborations with industry and academia for his institute(s) and staff, including but not limited to pharmaceutical companies such as Bayer, Boehringer Ingelheim, Bosch, Roche and other companies such as Siemens, IBA, Varian, Elekta, Bruker, etc. In this role, he was/is also responsible for the commercial technology transfer activities of his institute(s), including the creation of start-ups and licensing. This includes the DKFZ-PSMA617 related patent portfolio [WO2015055318 (A1), ANTIGEN (PSMA)] and similar IP portfolios. Dr. Baumann confirms that, to the best of his knowledge, none of the above funding sources were involved in the preparation of this paper. Other co-authors declare that they have no conflict of interest.
Figures








Similar articles
-
Targeting glutamine metabolism and autophagy: the combination for prostate cancer radiosensitization.Autophagy. 2021 Nov;17(11):3879-3881. doi: 10.1080/15548627.2021.1962682. Epub 2021 Sep 5. Autophagy. 2021. PMID: 34486482 Free PMC article.
-
Disruption of glutamine transport uncouples the NUPR1 stress-adaptation program and induces prostate cancer radiosensitivity.Cell Commun Signal. 2025 Jul 24;23(1):351. doi: 10.1186/s12964-025-02344-3. Cell Commun Signal. 2025. PMID: 40707944 Free PMC article.
-
Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.Theranostics. 2020 May 16;10(14):6411-6429. doi: 10.7150/thno.42602. eCollection 2020. Theranostics. 2020. PMID: 32483461 Free PMC article.
-
Therapeutic Targeting of Glutaminolysis as a Novel Strategy to Combat Cancer Stem Cells.Int J Mol Sci. 2022 Dec 4;23(23):15296. doi: 10.3390/ijms232315296. Int J Mol Sci. 2022. PMID: 36499623 Free PMC article. Review.
-
Targeting GLS1 to cancer therapy through glutamine metabolism.Clin Transl Oncol. 2021 Nov;23(11):2253-2268. doi: 10.1007/s12094-021-02645-2. Epub 2021 May 23. Clin Transl Oncol. 2021. PMID: 34023970 Review.
Cited by
-
Glutamine Transporter SLC1A5 Regulates Ionizing Radiation-Derived Oxidative Damage and Ferroptosis.Oxid Med Cell Longev. 2022 Oct 10;2022:3403009. doi: 10.1155/2022/3403009. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 36262284 Free PMC article.
-
Targeting glutamine metabolism and autophagy: the combination for prostate cancer radiosensitization.Autophagy. 2021 Nov;17(11):3879-3881. doi: 10.1080/15548627.2021.1962682. Epub 2021 Sep 5. Autophagy. 2021. PMID: 34486482 Free PMC article.
-
The Metabolic Landscape of Cancer Stem Cells: Insights and Implications for Therapy.Cells. 2025 May 15;14(10):717. doi: 10.3390/cells14100717. Cells. 2025. PMID: 40422220 Free PMC article. Review.
-
Cancer stem cells: advances in biology and clinical translation-a Keystone Symposia report.Ann N Y Acad Sci. 2021 Dec;1506(1):142-163. doi: 10.1111/nyas.14719. Epub 2021 Nov 30. Ann N Y Acad Sci. 2021. PMID: 34850398 Free PMC article. Review.
-
Metabolic changes during prostate cancer development and progression.J Cancer Res Clin Oncol. 2023 May;149(5):2259-2270. doi: 10.1007/s00432-022-04371-w. Epub 2022 Sep 23. J Cancer Res Clin Oncol. 2023. PMID: 36151426 Free PMC article. Review.
References
-
- Krause M, Dubrovska A, Linge A, Baumann M. Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev. 2017;109:63–73. - PubMed
-
- Peitzsch C, Gorodetska I, Klusa D, Shi Q, Alves TC, Pantel K, Metabolic regulation of prostate cancer heterogeneity and plasticity. Semin Cancer Biol. 2020. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous